255 related articles for article (PubMed ID: 34106030)
1. Giant cell arteritis: what is new in the preclinical and early clinical development pipeline?
Harkins P; Conway R
Expert Opin Investig Drugs; 2022 Sep; 31(9):921-932. PubMed ID: 34106030
[TBL] [Abstract][Full Text] [Related]
2. The role of biologics in the treatment of giant cell arteritis.
González-Gay MA; Pina T; Prieto-Peña D; Calderon-Goercke M; Blanco R; Castañeda S
Expert Opin Biol Ther; 2019 Jan; 19(1):65-72. PubMed ID: 30513026
[TBL] [Abstract][Full Text] [Related]
3. Current and emerging diagnosis tools and therapeutics for giant cell arteritis.
González-Gay MA; Pina T; Prieto-Peña D; Calderon-Goercke M; Blanco R; Castañeda S
Expert Rev Clin Immunol; 2018 Jul; 14(7):593-605. PubMed ID: 29877748
[TBL] [Abstract][Full Text] [Related]
4. Treatment of giant cell arteritis.
González-Gay MÁ; Pina T; Prieto-Peña D; Calderon-Goercke M; Gualillo O; Castañeda S
Biochem Pharmacol; 2019 Jul; 165():230-239. PubMed ID: 31034796
[TBL] [Abstract][Full Text] [Related]
5. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature.
Kötter I; Henes JC; Wagner AD; Loock J; Gross WL
Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S114-29. PubMed ID: 22640655
[TBL] [Abstract][Full Text] [Related]
6. Ustekinumab for refractory giant cell arteritis: A prospective 52-week trial.
Conway R; O'Neill L; Gallagher P; McCarthy GM; Murphy CC; Veale DJ; Fearon U; Molloy ES
Semin Arthritis Rheum; 2018 Dec; 48(3):523-528. PubMed ID: 29776658
[TBL] [Abstract][Full Text] [Related]
7. Recent Advances in Giant Cell Arteritis.
Guevara M; Kollipara CS
Curr Rheumatol Rep; 2018 Apr; 20(5):25. PubMed ID: 29611005
[TBL] [Abstract][Full Text] [Related]
8. New Therapeutic Approaches to Large-Vessel Vasculitis.
Kaymakci MS; Warrington KJ; Kermani TA
Annu Rev Med; 2024 Jan; 75():427-442. PubMed ID: 37683286
[TBL] [Abstract][Full Text] [Related]
9. Comparing treatment options for large vessel vasculitis.
Macaluso F; Marvisi C; Castrignanò P; Pipitone N; Salvarani C
Expert Rev Clin Immunol; 2022 Aug; 18(8):793-805. PubMed ID: 35714219
[TBL] [Abstract][Full Text] [Related]
10. [From pathogenesis of giant cell arteritis to new therapeutic targets].
Samson M; Bonnotte B
Rev Med Interne; 2017 Oct; 38(10):670-678. PubMed ID: 28800947
[TBL] [Abstract][Full Text] [Related]
11. Biologic Therapies for Giant Cell Arteritis.
Harrington R; Al Nokhatha SA; Conway R
Biologics; 2021; 15():17-29. PubMed ID: 33442231
[TBL] [Abstract][Full Text] [Related]
12. Giant cell arteritis.
Pepper K
Postgrad Med; 2023 Jan; 135(sup1):22-32. PubMed ID: 37021621
[TBL] [Abstract][Full Text] [Related]
13. Giant cell arteritis and innovative treatments.
Costanzo G; Ledda AG; Sambugaro G
Curr Opin Allergy Clin Immunol; 2023 Aug; 23(4):327-333. PubMed ID: 37357797
[TBL] [Abstract][Full Text] [Related]
14. Current advances in the treatment of giant cell arteritis: the role of biologics.
Low C; Conway R
Ther Adv Musculoskelet Dis; 2019; 11():1759720X19827222. PubMed ID: 30800174
[TBL] [Abstract][Full Text] [Related]
15. Giant cell arteritis: pathogenic mechanisms and new potential therapeutic targets.
Koster MJ; Warrington KJ
BMC Rheumatol; 2017; 1():2. PubMed ID: 30886946
[TBL] [Abstract][Full Text] [Related]
16. Blocking GM-CSF receptor α with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis.
Corbera-Bellalta M; Alba-Rovira R; Muralidharan S; Espígol-Frigolé G; Ríos-Garcés R; Marco-Hernández J; Denuc A; Kamberovic F; Pérez-Galán P; Joseph A; D'Andrea A; Bondensgaard K; Cid MC; Paolini JF
Ann Rheum Dis; 2022 Apr; 81(4):524-536. PubMed ID: 35045965
[TBL] [Abstract][Full Text] [Related]
17. Tocilizumab for the treatment of giant cell arteritis.
Schirmer M; Muratore F; Salvarani C
Expert Rev Clin Immunol; 2018 May; 14(5):339-349. PubMed ID: 29676602
[TBL] [Abstract][Full Text] [Related]
18. Biological treatments in giant cell arteritis & Takayasu arteritis.
Samson M; Espígol-Frigolé G; Terrades-García N; Prieto-González S; Corbera-Bellalta M; Alba-Rovira R; Hernández-Rodríguez J; Audia S; Bonnotte B; Cid MC
Eur J Intern Med; 2018 Apr; 50():12-19. PubMed ID: 29146018
[TBL] [Abstract][Full Text] [Related]
19. Treatment of giant-cell arteritis: from broad spectrum immunosuppressive agents to targeted therapies.
Cid MC; Ríos-Garcés R; Terrades-García N; Espígol-Frigolé G
Rheumatology (Oxford); 2020 May; 59(Suppl 3):iii17-iii27. PubMed ID: 32348525
[TBL] [Abstract][Full Text] [Related]
20. Advances in the Treatment of Giant Cell Arteritis.
Castañeda S; Prieto-Peña D; Vicente-Rabaneda EF; Triguero-Martínez A; Roy-Vallejo E; Atienza-Mateo B; Blanco R; González-Gay MA
J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
